Cell death and learning impairment in mice caused by in vitro modified pro-NGF can be related to its increased oxidative modifications in Alzheimer disease

American Journal of Pathology

Volumn 175, Issue 6, 2009, Pages 2574-2585

  Kichev, Anton ^a   Ilieva, Ekaterina V ^a   Piñol Ripoll, Gerard ^a   Podlesniy, Petar ^a   Ferrer, Isidro ^b   Portero Otín, Manue ^a   Pamplona, Reinald ^a   Espinet, Carme ^a  

^a UNIVERSITY OF LLEIDA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; NERVE GROWTH FACTOR; NEUROTROPHIN; NEUROTROPHIN RECEPTOR P75;

ADULT; AEROBIC METABOLISM; AGED; ALZHEIMER DISEASE; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DEATH; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; GLYCATION; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LEARNING DISORDER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; WESTERN BLOTTING;

EID: 73549125459     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090018     Document Type: Article

References (36)

1. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G: Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 2000, 1502:139-144
2. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR: Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005, 64:1152-1156
3. Pamplona R, Dalfo E, Ayala V, Bellmunt MJ, Prat J, Ferrer I, Portero-Otin M: Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 2005, 280: 21522-21530
4. Butterfield DA, Gnjec A, Poon HF, Castegna A, Pierce WM, Klein JB, Martins RN: Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J Alzheimers Dis 2006, 10:391-397
5. Korolainen MA, Goldsteins G, Nyman TA, Alafuzoff I, Koistinaho J, Pirttila T: Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain. Neurobiol Aging 2006, 27:42-53
6. Sultana R, Perluigi M, Butterfield DA: Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). J Chromatogr B Analyt Technol Biomed Life Sci 2006, 833:3-11
7. Williams TI, Lynn BC, Markesbery WR, Lovell MA: Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 2006, 27:1094-1099
8. Pamplona R, Ilieva E, Ayala V, Bellmunt MJ, Cacabelos D, Dalfo E, Ferrer I, Portero-Otin M: Maillard reaction versus other nonenzymatic modifications in neurodegenerative processes. Ann NY Acad Sci 2008, 1126:315-319
9. Pamplona R: Membrane phospholipids, lipoxidative damage and molecular integrity: a causal role in aging and longevity. Biochim Biophys Acta 2008, 1777:1249-1262
10. Roberts LJ 2nd, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD: Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998, 273:13605-13612
11. Nourooz-Zadeh J, Liu EH, Anggard E, Halliwell B: F4-isoprostanes: a novel class of prostanoids formed during peroxidation of docosahexaenoic acid (DHA). Biochem Biophys Res Commun 1998, 242:338-344
12. Fahnestock M, Michalski B, Xu B, Coughlin MD: The precursor pronerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 2001, 18:210-220
13. Pedraza CE, Podlesniy P, Vidal N, Arevalo JC, Lee R, Hempstead B, Ferrer I, Iglesias M, Espinet C: Pro-NGF isolated from the human brain affected by Alzheimer's disease induces neuronal apoptosis mediated by p75NTR. Am J Pathol 2005, 166:533-543
14. Podlesniy P, Kichev A, Pedraza C, Saurat J, Encinas M, Perez B, Ferrer I, Espinet C: Pro-NGF from Alzheimer's disease and normal human brain displays distinctive abilities to induce processing and nuclear translocation of intracellular domain of p75NTR and apoptosis. Am J Pathol 2006, 169:119-131
15. Lee R, Kermani P, Teng KK, Hempstead BL: Regulation of cell survival by secreted proneurotrophins. Science 2001, 294:1945-1948
16. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, Jacobsen C, Kliemannel M, Schwarz E, Willnow TE, Hempstead BL, Petersen CM: Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004, 427:843-848
17. Harrington AW, Leiner B, Blechschmitt C, Arevalo JC, Lee R, Morl K, Meyer M, Hempstead BL, Yoon SO, Giehl KM: Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl Acad Sci USA 2004, 101:6226-6230
18. Yiangou Y, Facer P, Sinicropi DV, Boucher TJ, Bennett DL, McMahon SB, Anand P: Molecular forms of NGF in human and rat neuropathic tissues: decreased NGF precursor-like immunoreactivity in human diabetic skin. J Peripher Nerv Syst 2002, 7:190-197
19. Reinshagen M, Geerling I, Eysselein VE, Adler G, Huff KR, Moore GP, Lakshmanan J: Commercial recombinant human beta-nerve growth factor and adult rat dorsal root ganglia contain an identical molecular species of nerve growth factor prohormone. J Neurochem 2000, 74:2127-2133
20. Mowla SJ, Pareek S, Farhadi HF, Petrecca K, Fawcett JP, Seidah NG, Morris SJ, Sossin WS, Murphy RA: Differential sorting of nerve growth factor and brain-derived neurotrophic factor in hippocampal neurons. J Neurosci 1999, 19:2069-2080
21. Edwards RH, Selby MJ, Garcia PD, Rutter WJ: Processing of the native nerve growth factor precursor to form biologically active nerve growth factor. J Biol Chem 1988, 263:6810-6815
22. Ullrich A, Gray A, Berman C, Dull TJ: Human beta-nerve growth factor gene sequence highly homologous to that of mouse. Nature 1983, 303:821-825
23. Braak H, Braak E, Peters A, Morrison JH, editors: Cerebral Cortex. New York, Kluwer Academic/Plenum Publishers, 1999 Vol 14:475-512
24. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K: Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006, 112:389-404
25. Ferrer I, Santpere G, Arzberger T, Bell J, Blanco R, Boluda S, Budka H, Carmona M, Giaccone G, Krebs B, Limido L, Parchi P, Puig B, Strammiello R, Strobel T, Kretzschmar H: Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks. A BrainNet Europe Study. J Neuropathol Exp Neurol 2007, 66:35-46
26. Ferrer I, Martinez A, Boluda S, Parchi P, Barrachina M: Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell Tissue Bank 2008, 9:181-194
27. Beattie MS, Harrington AW, Lee R, Kim JY, Boyce SL, Longo FM, Bresnahan JC, Hempstead BL, Yoon SO: ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron. 2002 36(3):375-386.
28. Rattenholl A, Lilie H, Grossmann A, Stern A, Schwarz E, Rudolph R: The pro-sequence facilitates folding of human nerve growth factor from Escherichia coli inclusion bodies. Eur J Biochem 2001, 268:3296-3303
29. Saez-Valero J, de Ceballos ML, Small DH, de Felipe C: Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid beta-peptide. Neurosci Lett 2002, 325:199-202
30. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML: Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005, 25:1904-1913
31. Seidah NG, Benjannet S, Pareek S, Savaria D, Hamelin J, Goulet B, Laliberte J, Lazure C, Chretien M, Murphy RA: Cellular processing of the nerve growth factor precursor by the mammalian pro-protein convertases. Biochem J 1996, 314(Pt 3):951-960
32. Cantero AV, Portero-Otin M, Ayala V, Auge N, Sanson M, Elbaz M, Thiers JC, Pamplona R, Salvayre R, Negre-Salvayre A: Methylglyoxal induces advanced glycation end product (AGEs) formation and dysfunction of PDGF receptor-beta: implications for diabetic atherosclerosis. FASEB J 2007, 21:3096-3106
33. Portero-Otin M, Pamplona R, Bellmunt MJ, Ruiz MC, Prat J, Salvayre R, Negre-Salvayre A: Advanced glycation end product precursors impair epidermal growth factor receptor signaling. Diabetes 2002, 51:1535-1542
34. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Munch G: Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 2005, 92:255-263
35. Chen F, Wollmer MA, Hoerndli F, Munch G, Kuhla B, Rogaev EI, Tsolaki M, Papassotiropoulos A, Gotz J: Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci USA 2004, 101: 7687-7692
36. Kuhla B, Haase C, Flach K, Luth HJ, Arendt T, Munch G: Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation. J Biol Chem 2007, 282: 6984-6991